ATE374251T1 - Zusammensetzungen zur gentherapie von diabetes - Google Patents

Zusammensetzungen zur gentherapie von diabetes

Info

Publication number
ATE374251T1
ATE374251T1 AT00916679T AT00916679T ATE374251T1 AT E374251 T1 ATE374251 T1 AT E374251T1 AT 00916679 T AT00916679 T AT 00916679T AT 00916679 T AT00916679 T AT 00916679T AT E374251 T1 ATE374251 T1 AT E374251T1
Authority
AT
Austria
Prior art keywords
compositions
diabetes
gene therapy
expressed
insulin
Prior art date
Application number
AT00916679T
Other languages
English (en)
Inventor
Matthew J During
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Application granted granted Critical
Publication of ATE374251T1 publication Critical patent/ATE374251T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00916679T 1999-02-19 2000-02-22 Zusammensetzungen zur gentherapie von diabetes ATE374251T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12097599P 1999-02-19 1999-02-19

Publications (1)

Publication Number Publication Date
ATE374251T1 true ATE374251T1 (de) 2007-10-15

Family

ID=22393646

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916679T ATE374251T1 (de) 1999-02-19 2000-02-22 Zusammensetzungen zur gentherapie von diabetes

Country Status (8)

Country Link
US (1) US6503887B1 (de)
EP (1) EP1153131B1 (de)
JP (1) JP2002540175A (de)
AT (1) ATE374251T1 (de)
AU (1) AU777988B2 (de)
CA (1) CA2364417C (de)
DE (1) DE60036537T2 (de)
WO (1) WO2000057921A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719950B2 (en) * 1995-06-07 2000-05-18 Yale University Oral delivery of adeno-associated viral vectors
CA2403205A1 (en) * 2000-03-13 2001-09-20 Engene, Inc. Compositions and methods of regulated protein expression in gut endocrine k cells
WO2002050264A2 (en) * 2000-12-18 2002-06-27 Wyeth Promoters and recombinant expression constructs
WO2002089855A1 (en) * 2001-04-27 2002-11-14 Auckland Uniservices Limited Peroral transduction of hepatocytes in the treatment of disease
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
FR2852247A1 (fr) * 2003-03-11 2004-09-17 Centre Nat Rech Scient Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
AU2007285472B2 (en) 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
EP2049518B1 (de) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
EP2091947A2 (de) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinaseaktivatoren
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2625270A4 (de) * 2010-10-08 2014-02-26 Univ Putra Malaysia Upm Glp-1-promoter-vermittelte insulinexpression zur behandlung von diabetes
US10696946B2 (en) 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
EP3233131A1 (de) * 2014-12-16 2017-10-25 Board of Regents of the University of Nebraska Gentherapie für juvenile neuronale ceroid-lipofuszinose
WO2017079448A1 (en) 2015-11-06 2017-05-11 The Board Of Trustees Of The University Of Illinois Ox40l-jagged-1 chimeric polypeptides and uses thereof
EP3475413B1 (de) 2016-06-22 2024-02-14 David Klatzmann Genetisch modifizierte t-lymphozyten
EP3565591A1 (de) 2017-01-06 2019-11-13 Stabilitech Biopharma Ltd Virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837693A (en) 1995-03-24 1998-11-17 The Regents Of The University Of California Intravenous hormone polypeptide delivery by salivary gland expression
US5885971A (en) 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
FR2732978B1 (fr) * 1995-04-14 1997-05-30 Inst Nat Sante Rech Med Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
US5646034A (en) * 1995-06-07 1997-07-08 Mamounas; Michael Increasing rAAV titer
AU719950B2 (en) 1995-06-07 2000-05-18 Yale University Oral delivery of adeno-associated viral vectors
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
US6225290B1 (en) * 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
ATE486614T1 (de) * 1997-03-14 2010-11-15 Philadelphia Children Hospital Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie

Also Published As

Publication number Publication date
JP2002540175A (ja) 2002-11-26
DE60036537T2 (de) 2008-06-19
EP1153131B1 (de) 2007-09-26
DE60036537D1 (de) 2007-11-08
US6503887B1 (en) 2003-01-07
AU3774700A (en) 2000-10-16
AU777988B2 (en) 2004-11-11
EP1153131A2 (de) 2001-11-14
CA2364417C (en) 2013-11-05
WO2000057921A3 (en) 2001-01-04
CA2364417A1 (en) 2000-10-05
WO2000057921A2 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2004080533A8 (en) Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue
AR047392A1 (es) Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
WO2004044181A3 (en) Antisense modulation of apolipoprotein b expression
WO2004069190A3 (en) Combination therapy for treating protein deficiency disorders
WO2004016224A3 (en) Antisense modulation of vegf co-regulated chemokine-1 expression
WO2003023000A3 (en) Linear dna fragments for gene expression
WO2004074450A8 (en) Combination therapy for treating protein deficiencies
WO2003097662A8 (en) Antisense modulation of apolipoprotein b expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
EP1660682A4 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
WO2004016754A3 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
IL145514A0 (en) Akt nucleic acids, polypeptides, and uses thereof
WO2003105755A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION
WO2001029175A3 (en) Antisense modulation of fra-1 expression
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2003012031A3 (en) Antisense modulation of stearoyl-coa desaturase expression
WO2020186207A3 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2004014299A3 (en) Antisense modulation of resistin expression
WO2003105754A3 (en) ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties